Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)
Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)
The purpose of this study is to assess the safety of OCV-501 in patients with AML who
 completed the Study 311-10-001 and were judged that there was no relapse by any inspections
 in the end of the study.
Inclusion Criteria:

 -  Patients who completed the Study 311-10-001 and were judged that there was no relapse
 by any inspections in the end of the study.

 -  Patients who are capable of giving informed consent

 Exclusion Criteria:

 -  Patients failed to discontinue the Study 311-10-001 even though patients met the
 discontinuation criteria.

 -  Patients who have participated in any other clinical trials , excluding the Study
 311-10-001).